2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Authors:
- Donald M. Lloyd-JonesDLDonald M. Lloyd-Jones
- Pamela B. MorrisPMPamela B. Morris
- Christie M. BallantyneCBChristie M. Ballantyne
- Kim K. BirtcherKBKim K. Birtcher
- David D. DalyDDDavid D. Daly
- Sondra M. DePalmaSDSondra M. DePalma
- Margo B. MinissianMMMargo B. Minissian
- Carl E. OrringerCOCarl E. Orringer
- Sidney C. SmithSSSidney C. Smith
Top Cited Papers
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice GuidelineAnnals of Internal Medicine, 2015
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Effects of Extended-Release Niacin with Laropiprant in High-Risk PatientsNew England Journal of Medicine, 2014
- 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular RiskJACC, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014
- Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)Heart, 2014
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005